Positive Patient Stories™

Investor Overview

Webcast ImageWebcast - Replay
Q2 2016 Paratek Pharmaceuticals Inc Earnings Conference Call
08/04/16 at 8:30 a.m. ET
Q2 2016 Paratek Pharmaceuticals Inc Earnings Conference Call
Thursday, August 4, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.10 (0.75%)
Data as of 08/26/16 4:00 p.m. ET

Latest News

Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results
Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016
Paratek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.